Popular immunotherapy target turns out to have a surprising buddy … – Science Daily
Science Daily |
Popular immunotherapy target turns out to have a surprising buddy …
Science Daily The majority of current cancer immunotherapies focus on PD-L1. This well-studied protein turns out to be controlled by a partner, CMTM6, a previously … |
